Case Details
- Citation: Combe International Ltd v Dr. August Wolff GmbH & Co. KG Arzneimittel [2020] SGIPOS 3
- Court: Intellectual Property Office of Singapore
- Date: 2020-02-21
- Judges: Ms Tan Mei Lin
- Plaintiff/Applicant: Combe International Ltd
- Defendant/Respondent: Dr. August Wolff GmbH & Co. KG Arzneimittel
- Legal Areas: Trade marks and trade names – Declaration of Invalidity
- Statutes Referenced: The Applicant relies on three grounds in the Trade Marks Act, Trade Marks Act
- Cases Cited: [2006] SGCA 14, [2009] SGCA 13, [2011] SGHC 176, [2012] SGCA 56, [2016] SGHC 131, [2016] SGCA 33, [2020] SGIPOS 3
- Judgment Length: 25 pages, 9,873 words
Summary
This case involves a dispute over the registration of the trade mark "VAGISAN" by Dr. August Wolff GmbH & Co. KG Arzneimittel (the "Proprietor") in Singapore. Combe International Ltd (the "Applicant") applied for a declaration of invalidity of the "VAGISAN" trade mark, arguing that it is confusingly similar to the Applicant's earlier registered "VAGISIL" trade marks. The Intellectual Property Office of Singapore had to determine whether the registration of the "VAGISAN" trade mark should be invalidated under Sections 8(2)(b), 8(4)(b)(i), and 8(7)(a) of the Trade Marks Act.
After considering the evidence and arguments presented by both parties, the Hearing Officer found that the "VAGISAN" trade mark was similar to the Applicant's earlier "VAGISIL" marks and covered identical or similar goods, creating a likelihood of confusion. The Hearing Officer therefore declared the registration of the "VAGISAN" trade mark invalid under Section 8(2)(b) of the Act.
What Were the Facts of This Case?
The Applicant, Combe International Ltd, is a company founded in America in 1949 that owns a range of brands in feminine health and intimate skin care, men's hair colour and grooming, and oral device care. Its key brand is "VAGISIL", which it has used in Singapore since 1989 and for which it holds several registered trade marks in the country.
The Proprietor, Dr. August Wolff GmbH & Co. KG Arzneimittel, is the medical division of the Dr. Wolff-Group, a cosmetics and pharmaceutical products company based in Germany. The Proprietor registered the trade mark "VAGISAN" in Singapore in 2012 for goods in Classes 3 and 5, including pharmaceutical and cosmetic products.
On 14 November 2017, the Applicant applied for a declaration of invalidity of the "VAGISAN" trade mark registration, arguing that it was confusingly similar to the Applicant's earlier "VAGISIL" marks and covered identical or similar goods, creating a likelihood of confusion for consumers.
What Were the Key Legal Issues?
The key legal issues in this case were:
1. Whether the "VAGISAN" trade mark was similar to the Applicant's earlier "VAGISIL" marks under Section 8(2)(b) of the Trade Marks Act.
2. Whether the goods covered by the "VAGISAN" trade mark were identical or similar to those covered by the Applicant's earlier "VAGISIL" marks under Section 8(2)(b).
3. If the first two issues were answered in the affirmative, whether there existed a likelihood of confusion on the part of the public under Section 8(2)(b).
The Applicant also raised two additional grounds for invalidation under Sections 8(4)(b)(i) and 8(7)(a) of the Act, but the Hearing Officer focused her analysis primarily on the Section 8(2)(b) ground.
How Did the Court Analyse the Issues?
The Hearing Officer applied the well-established "step-by-step" approach set out by the Singapore Court of Appeal in Staywell Hospitality Group Pty Ltd v Starwood Hotels & Resorts Worldwide, Inc [2014] 1 SLR 911 for assessing likelihood of confusion under Section 8(2)(b).
On the first step of mark similarity, the Hearing Officer found that the "VAGISAN" mark was visually and aurally similar to the Applicant's "VAGISIL" marks, differing only by the final two letters. She also found that the marks were conceptually similar, as they both evoked the idea of "vaginal" products.
On the second step of goods similarity, the Hearing Officer determined that the goods covered by the "VAGISAN" mark (which included pharmaceutical and cosmetic products for vaginal care) were identical or highly similar to the goods covered by the Applicant's "VAGISIL" marks (which included medicated and non-medicated feminine hygiene products).
Having found that the first two steps were satisfied, the Hearing Officer then considered the third step of likelihood of confusion. She noted that the high degree of similarity between the marks and the identity/similarity of the goods meant that consumers were likely to be confused and believe the "VAGISAN" products were part of the Applicant's "VAGISIL" brand or were otherwise economically linked.
The Hearing Officer therefore concluded that the registration of the "VAGISAN" mark should be declared invalid under Section 8(2)(b) of the Act.
What Was the Outcome?
The Hearing Officer declared the registration of the "VAGISAN" trade mark invalid under Section 8(2)(b) of the Trade Marks Act. This means the "VAGISAN" trade mark registration has been cancelled and the Proprietor can no longer use or enforce that mark in Singapore.
Why Does This Case Matter?
This case is significant for a few reasons:
Firstly, it demonstrates the importance of conducting thorough trademark clearance searches before adopting and registering a new mark. The Proprietor's selection of the "VAGISAN" mark, which was found to be confusingly similar to the Applicant's well-known "VAGISIL" brand, ultimately led to the invalidation of its trade mark registration.
Secondly, the case highlights the high bar that must be met to overcome a likelihood of confusion finding under Section 8(2)(b) of the Trade Marks Act. Even where the competing marks are not identical, a high degree of similarity combined with identical or similar goods can still result in a successful invalidation action.
Finally, the case is a reminder that trade mark owners must be vigilant in policing their marks and challenging potentially infringing registrations, even in jurisdictions where they may not have an active presence. The Applicant's proactive enforcement of its "VAGISIL" rights in Singapore, despite being a US-based company, ultimately paid off in this case.
Legislation Referenced
Cases Cited
- [2006] SGCA 14
- [2009] SGCA 13
- [2011] SGHC 176
- [2012] SGCA 56
- [2016] SGHC 131
- [2016] SGCA 33
- [2020] SGIPOS 3
Source Documents
This article analyses [2020] SGIPOS 3 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.